Literature DB >> 21263421

Intraoperative hybrid cardiac surgery for neonates and young children with congenital heart disease: 5 years of experience.

Shou-Jun Li1, Hao Zhang, Xiang-Dong Sheng, Jun Yan, Xi-Cheng Deng, Wei-Dan Chen, Sheng-Shou Hu.   

Abstract

OBJECTIVE: This study intends to summarize 5 years of intraoperative hybrid procedure (IHP) experience with neonates and young children having congenital heart disease (CHD).
METHODS: From March 2003 to March 2009, a total of 152 consecutive patients younger than 2 years old who had undergone IHP were enrolled. In the balloon plasty group (n = 72), transventricular pulmonary valvuloplasty, or transaortic balloon dilatation were performed for pulmonary atresia, pulmonary stenosis, or coactation of the aorta. In the device group (n = 43), transventricular device closure was performed for ventricular septal defect (VSD), or transatrial device closure for atrial septal defect (ASD). In the collateral arteries occlusion group (n = 37), the major aortopulmonary collateral arteries (MPCAs) were occluded with coils for tetralogy of Fallot or other cyanotic CHDs. All procedures were image guided and performed in a specially designed hybrid operation room. All surviving patients were followed up, and the major adverse cardiovascular events that occurred were recorded.
RESULTS: In the balloon plasty group, all patients received successful transventricular valvuloplasty or transaortic balloon angioplasty. However, severe right ventricle outflow obstruction was observed in 2 cases. One patient was transferred to regular open-heart surgery immediately, and another underwent regular open-heart procedure after discharge. Furthermore, 1 neonate with pulmonary atresia with intact ventricular septum died from liver failure 6 months after IHP. In the device closure group, the device closure failed to be performed in 3 cases (2 with ASD and 1 with VSD). One young child with VSD died from pneumonia, even after successful device closure. No device malposition was observed in the device closure group during follow-up. All patients who received MPCA occlusion and associated open-heart correction were eventually discharged.
CONCLUSION: IHP could avoid or shorten the application of cardiopulmonary bypass and reduce surgical trauma for selected young children with CHD. Although IHP is feasible and safe, the image outfits, image-guided technology, and IHP-related devices should be developed and improved.

Entities:  

Mesh:

Year:  2010        PMID: 21263421

Source DB:  PubMed          Journal:  Ann Thorac Cardiovasc Surg        ISSN: 1341-1098            Impact factor:   1.520


  5 in total

1.  Surgical Management of Vascular Stents in Pediatric Cardiac Surgery: Clues for a Staged Partnership.

Authors:  Juan-Miguel Gil-Jaurena; José-Luis Zunzunegui; Ramón Pérez-Caballero; Ana Pita; María-Teresa González-López; Fernando Ballesteros; Alejandro Rodríguez; Constancio Medrano
Journal:  Pediatr Cardiol       Date:  2015-06-26       Impact factor: 1.655

2.  Two approaches for newborns with critical congenital heart disease: a comparative study.

Authors:  Guan-Xi Wang; Kai Ma; Kun-Jing Pang; Xu Wang; Lei Qi; Yang Yang; Feng-Qun Mao; Shou-Jun Li
Journal:  World J Pediatr       Date:  2021-11-25       Impact factor: 2.764

3.  "One-stop" Hybrid approach for tetralogy of fallot with aortopulmonary collateral arteries in adults.

Authors:  Yiyao Jiang; Wei Zhang; Yu Pei; Li Yang; Langang Xue; Xiaocheng Liu
Journal:  Pak J Med Sci       Date:  2013-04       Impact factor: 1.088

4.  Hybrid closure of atrial septal defect: A modified approach.

Authors:  Kshitij Sheth; Shreepal Jain; Suresh Joshi; Bharat Dalvi
Journal:  Ann Pediatr Cardiol       Date:  2015 Jan-Apr

5.  Transthoracic Balloon Pulmonary Valvuloplasty for Treatment of Congenial Pulmonary Atresia Patients with Intact Ventricular Septum.

Authors:  Zhi-Qin Lin; Qiang Chen; Hua Cao; Liang-Wan Chen; Gui-Can Zhang; Dao-Zhong Chen; Qin-Min Wang; Han-Fan Qiu; Dong-Shan Liao; Feng Lin
Journal:  Med Sci Monit       Date:  2017-10-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.